| Name | Title | Contact Details |
|---|
Coloplast is among the world’s leading suppliers of intimate healthcare products and services. As a group, we have built our current position by listening to consumers and understanding their needs. For more than 50 years, Coloplast has developed and marketed innovative products that make life easier for people with diseases of a personal and private nature. Our focus is centered on ostomy care, continence care, urology care and skin and wound care.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.
We consistently strive to deliver unparalleled service, high quality results.
Fresenius SE & Co. KGaA is a health care company based in Bad Homburg vor der Höhe, Germany.
WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.